IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chengzhi Zhang, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/US2004/025480

Title: Benzofuran Derivatives Useful for Treating Hyper-Proliferative Disorders

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY 37 C.F.R. 1.97(b)(2)

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying form(s) PTO/SB/08A-B [substitute for form 1449/PTO]. A copy of the International Search Report is also enclosed for your reference.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

William F. Gray Reg. No.: 31,018 Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation 400 Morgan Lane

West Haven, CT 06516 Telephone: (203) 812-2226 Facsimile: (203) 812-6459

IAP5 Rec'd PCT/PTO 27 JAN 2006 10/566343

PTO/SB/08A (07-05)

Approved for use through 07/31/2006, OMB 0551-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Papenwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.						
Substitute for form 1449/PTO	Complete if Known					
	Application Number	[to be assigned]				
INFORMATION DISCLOSURE	Filing Date					
	First Named Inventor	Chengzhi Zhang				
STATEMENT BY APPLICANT Art Unit OFFICIAL STREET						
(Use as many sheets as necessary)	Examiner Name					
Sheet 1 of 2	Attomey Docket Number	5168				

			U. S. PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ^{2 (F known)}			Figures Appear	
	l	US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-			_	
		US-				
		Us-				
		US-			· · · · · · · · · · · · · · · · · · ·	
		US-				
		US-	1		-	
-		US-	1			
		Us-	1			
		US-			1	
		US-	 		 	
		US-	1			
		US-				
	-	110.	_			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication	Name of Patentes or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Т	
		Country Code ³ "Number * "Kind Code ⁶ (If known)	MM-DD-YYYY		Or Ralavant Figures Appear	™	
/N.C./	F1	WO 03/072561 A1	09-04-2003	Bayer Pharmaceuticals	Corporation		
/N:C	F2	EP 0 731 097 A1	09-11-1996	Eli Lilly and Company			
/N.C.							
	_					L	
	i					г	

Signature Connie EXAMBLES: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Taw line through citation is not in conformance and not considered, include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Krints Codes of USPTO Patent Decrements at www.sept.copy or VMPEP 900.04. *Enter Critical testises due documents, by the two-tester code (WIPO Standard ST.3). *For Critical Papareses patent documents, he indication of the year of the reign of the Emperior must precede the serial number of the patent document. *Mind of document of the appropriate symbolic as indicated on the document under WIPO Standard ST.1 of possible. *Applicant is to place and endor whether the effects in the appropriate symbolic as indicated on the document under WIPO Standard ST.1 of possible. *Applicant is to place and endor whether the Emperior must precede the serial number of the patent document. *Mind of document should be appropriate symbolic as included on the document under WIPO Standard ST.1 of possible. *Applicant is to place and endor whether the standard standard

the appropriate symbols as infloided on the occument under WPU'S standard stifl if possible. "Applicant is to place a cinece man, neer turginal naguage to the propriate symbols and propriate symbols and propriate symbols." It is placed to the propriate symbols and possible symbols are the propriate symbols and application. Confidentially is governed by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, useful to the propriate symbols and application. Confidentially is governed by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete the propriate symbols. The propriate symbols are symbols and propriate symbols are symbols and propriate symbols. The propriate symbols are symbols and propriate symbols and propriate symbols. The propriate symbols are symbols and propriate symbols are symbols. The propriate symbols are symbols and propriate symbols are symbols and propriate symbols. The propriate symbols are symbols and propriate symbols. The propriate symbols are symbols and propriate symbols. The propriate symbols are symbols are symbols and propriate symbols. The propriate symbols are symbols are symbols are symbols and propriate symbols. The propriate symbols are symbols are symbols and propriate symbols. The propriate symbols are symbols are symbols are symbols and propriate symbols. The propriate symbols are symbols are symbols are symbols and propriate symbols. The propriate symbols are symbols are symbols are symbols and propriate symbols. The symbols are symbols are symbols are symbols are symbols are symbols are symbols. The symbols are symbols are symbols are symbols are symbols are symbols are symbols. The symbols are symbols are symbols are symbols are symbols are symbols are symbols. The symbols are symbols. The symbols are symbol

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

IAP5 Rec'd PCT/PTO 27 JAN 2006

PTO/\$B/08B (07-05)

	Une	ser the Paperwork Rec	fuction Ac	t of 1995, no persons a		and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it contains a valid OMB control number.		
Substitute for form 1449/PTO					Complete if Known			
1					Application Number	[to be assigned] / 566343		
	INFORMATION DISCLOSURE				Filing Date			
ı	STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Chengzhi Zhang		
I		(Use as many she	ets as m	cessand	Art Unit			
Į		(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Examiner Name			
•	Sheet	2	of	2	Attorney Docket Number	5168		

NON PATENT LITERATURE DOCUMENTS Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of					
nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
4.C./	R1	Hayakawa, I., et al., "4-Hydroxy-3-methyl-6-phenylbenzofuran-2-carboxylic Acid Ethyl Ester Derivatives as Potent Anti-tumor Agents", Bloorg. Med. Chem. Lett. 14: 455-458 (2004)			
/N.C	./ R2	Hayakawa, I., et al., "Thienopyridine and Benzofuran Derivatives as Potent Anti-tumor Agents Possessing Different Structure-activity Relationships", Bloorg, Med. Chem. Lett. 14: 3411-3414 (2004)			
N.C./	R3	Hayakawa, I., et al., "A Library Synthesis of 4-Hydroxy-3-Methyl-6-Phenylbenzofuran-2-carboxylic Acid Ethyl Ester Derivatives as Anti-tumor Agents", Bloorg. Med. Chem. Lett. 14: 4383-4387 (2004)			
			_		
			_		

	Examiner	/Nizal Chandrakumar/	Date	04/26/2008
	Signature		Considered	
-	*EXAMINER: In	itial if reference considered, whether or not citation is in conformance with MOED 60	O Drow line through a	Station If not in conformance and not

*EXAMMER: initial if reference considered, whether or not clation is in conformance with MPCP 608. Draw like through claim if not in conformance and not considered, include copy of this form with next communication to applicant.

1 Applicant's unique clatifier designation number (optional). Applicant is to place a check mark here if English language Translation is attacked. The interest is to the first option of the conformance and not receive the complete of the property of the public which is to the fand by the UBPTO Translation is the conformance and not receive the completed application form to the UBPTO. Time will vary depending upon the individual case. Any comments on the mount of time you require to complete this form and/or suppositions for reducing this burden, should be sent to the Chief information Officer, IV.3 Patent and Trademark Officer, PO. Bos. 1409, Alexandria, VA 22313-1430. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO. Bos. 1409, Alexandria, VA 22313-1430.